Physician profile
Gregory Smith
NPI 1043899834
$1,317.83
in general payments reported to CMS, 2019-2025
14 companies · $968 in 2025
The $968 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $350 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $279.29 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $275.74 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $241.44 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $184.08 | 2024-2025 | Evenity, Repatha, Otezla |
| Dynavax Technologies Corporation | $57.09 | 2024-2025 | Heplisav-B |
| Exact Sciences Corporation | $51.05 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.27 | 2025 | |
| Sumitomo Pharma America, INC. | $42.19 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $36.07 | 2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $34.08 | 2024 | Veozah |
| Ibsa Pharma INC. | $23.48 | 2025 | Flector, Licart, Tirosint |
| Abbvie INC. | $18.55 | 2024 | |
| Merck Sharp & Dohme LLC | $17.83 | 2025 | Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.67 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.